Articles related to OBESITY/WEIGHT MANAGEMENT

“We try to deescalate pharmacotherapy as soon as we can in children. How’s this going to affect puberty? How’s it going to affect growth? We don’t have those long-term data.”

Patients taking GLP-1 receptor agonists lose an average of 7 percent of their facial volume for every 22 pounds lost, mostly from fat pads in the midface—yet clinical trials rarely report facial fat loss as an adverse effect, leaving providers unlikely to counsel patients pretreatment about undesirable facial appearance changes.

“We need automatic, size-based dose modulation as the default instead of as an optional setting buried in the CT console menu. Too many departments still use ‘one-size-fits-all’ protocols, which means obese patients get doses far above what’s necessary for diagnostic quality.” – Dr. Jorge Green, Bariatric Surgeon

In the STEER study, patients using Wegovy® had greater cardiovascular improvements compared to tirzepatide, indicating that the same CV benefit cannot be generalized across other molecules in the GLP-1 or GIP/GLP-1 classes and may come specifically from the semaglutide molecule.

Although cost savings were observed with 5% weight loss, uncertainty surrounding cost savings accounting for the cost of more recently approved interventions remains.

“The study suggests that excessive calorie intake, particularly from ultra-processed foods, which are designed to be hyper-palatable and easy to overconsume by reducing satiety, is more strongly associated with higher body fat percentage and BMI than low levels of physical activity.”